Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index
September 17 2019 - 7:30AM
Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability
World Index
Biogen Inc. (Nasdaq: BIIB) today announced that it has been
ranked the #1 biotechnology company on the Dow Jones Sustainability
World Index (DJSI World) for the fourth time, after being the first
U.S.-based biotech company to ever make the list in 2013.
DJSI World recognizes the top 10 percent of companies in the
S&P Global Broad Market Index for their long-term commitment to
environmental, social and governance performance. Of the 318
companies named to DJSI World, Biogen led the biotechnology
industry, with top scoring in multiple areas, including addressing
cost burden, marketing practices, environmental reporting, policies
and management systems, human rights, climate strategy and human
capital development.
“As pioneers in neuroscience, we care deeply about making a
difference – whether that means our commitment to patients, our
employees, the environment or the communities where we live and
work,” said Michel Vounatsos, Chief Executive Officer of Biogen.
“This recognition is a testament to our talented employees around
the globe, who live our values in everything they do with a
patient-first approach. By making sustainability core to our own
DNA, we are building a stronger Biogen to inspire the scientists of
the future.”
Additional information regarding Biogen’s commitment to
sustainability can be found in its Corporate Social Responsibility
Report, which is based on internationally recognized Global
Reporting Initiative (GRI) G4 Guidelines
www.biogen.com/csrreport.
About Biogen Inc.At Biogen, our mission is
clear: we are pioneers in neuroscience. Biogen discovers, develops
and delivers worldwide innovative therapies for people living with
serious neurological and neurodegenerative diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners
Walter Gilbert and Phillip Sharp, and today has the leading
portfolio of medicines to treat multiple sclerosis, has introduced
the first approved treatment for spinal muscular atrophy,
commercializes biosimilars of advanced biologics and is focused on
advancing research programs in multiple sclerosis and
neuroimmunology, neuromuscular disorders, movement disorders,
Alzheimer's disease and dementia, ophthalmology, immunology,
neurocognitive disorders, acute neurology and pain.
We routinely post information that may be important to investors
on our website at www.biogen.com. To learn more, please
visit www.biogen.com and follow us on social media
– Twitter, LinkedIn, Facebook, YouTube.
MEDIA CONTACT:David
Caouette +1 617 679 4945public.affairs@biogen.com |
INVESTOR CONTACT:Joe Mara+1 781
464 2442IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
From Jul 2024 to Jul 2024
Biogen (TG:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024